Abstracts tagged "hyperuricemia"

Abstract Number: 0658 • ACR Convergence 2020
Identification of Two Novel Dysfunctional Variants in a Physiologically Important Urate Transporter ABCG2 in Paediatric-onset Familial Hyperuricemia and Gout Patients in Three Generations
Blanka Stiburkova¹, Yu Toyoda², Katerina Pavelcova¹, Jana Bohata¹, Pavel Ješina³, Yu Kubota², Tappei Takada² and Hiroshi Suzuki², ¹Institute of Rheumatology, Prague, Czech Republic, ²Department of Pharmacy, The University of Tokyo Hospital, Tokyo, Japan, Tokyo, Japan, ³Department of Pediatrics and Adolescent Medicine, First Faculty of Medicine, Charles University and General University Hospital in Prague, Prague, Czech Republic
Background/Purpose: ABCG2 is a high-capacity urate transporter gene. Common dysfunctional variants of ABCG2 that result in decreased urate excretion in humans are major causes of…
Abstract Number: 0664 • ACR Convergence 2020
Uric Acid Level Is Associated with Severity of Heart Failure with Preserved Ejection Fraction
Ana B. Arevalo¹, Alba Munoz², Faris Haddadin², Karan Sud², Gustavo Contreras², Shane Murray², Yousaf Ali² and Edgar Argulian², ¹Mount Sinai St. Luke's-West/ Icahn School of Medicine, New York, NY, ²Mount Sinai St. Luke's-West/ Icahn School of Medicine, New York
Background/Purpose: Hyperuricemia (HUC) has been shown to have an impact in the left atrium and left ventricle remodeling leading to the development of heart failure…
Abstract Number: 0667 • ACR Convergence 2020
Gout Management Beyond Prescription Writing: The Role of the Pharmacist
Emma Dorris¹, Paul Ryan², Mariosa Kieran³, Nicola Dalbeth⁴ and Geraldine McCarthy⁵, ¹School of Medicine, Dublin, Dublin, Ireland, ²Mayfield Family Practice, Cork, Cork, Ireland, ³Pharmacy Department, Dublin, Dublin, Ireland, ⁴University of Auckland, Auckland, New Zealand, ⁵University College Dublin, Dublin, Dublin, Ireland
Background/Purpose: Urate lowering therapy (ULT) is recommended for long-term gout management. However, gout flares are common at the time of starting ULT, and these flares…
Abstract Number: 0674 • ACR Convergence 2020
Disease Control of Hyperuricemia Newly Detected by Medical Check-up: A Retrospective Cohort Study of Health Insurance Claims Data in Japan
Ruriko Koto¹, Akihiro Nakajima¹, Hideki Horiuchi¹ and Hisashi Yamanaka², ¹Teijin Pharma Limited, Tokyo, Japan, ²Sanno Medical Center, Tokyo, Japan
Background/Purpose: Japanese guidelines for managing gout and hyperuricemia recommend the initiation of urate-lowering therapy (ULT) to prevent gouty arthritis in subjects having asymptomatic hyperuricemia with…
Abstract Number: 0675 • ACR Convergence 2020
AR882, a Potent and Selective Uricosuric Agent, Significantly Reduced Serum Urate Levels Following Multiple Ascending Once-Daily Doses in Healthy Subject Volunteers
Zancong Shen¹, Elizabeth Polvent², Vijay Hingorani², Andrea Clouser-Roche², Chris Mikelatis², Rongzi Yan², Shunqi Yan² and Li-Tain Yeh², ¹Arthrosi therapeutics, Laguna Hills, CA, ²Arthrosi Therapeutics Inc, Laguna Hills, CA
Background/Purpose: AR882 is a potent and selective uric acid transporter 1 (URAT1) inhibitor under development for the treatment of hyperuricemia or gout. AR882 exhibited linear…
Abstract Number: 0685 • ACR Convergence 2020
The Impact of Azathioprine on the Frequency of Persistent Responsiveness to Pegloticase in Patients with Chronic Refractory Gout
Herbert S. Baraf¹, Hope Rainey², Peter Lipsky² and Peter Lipsky³, ¹The Ctr for Rheumatology and Bone Research, Wheaton, MD, ²AMPEL BioSolutions LLC., Charlottesville, VA, ³RILITE Foundation, Charlottesville, VA
Background/Purpose: Pegloticase is a mammalian recombinant uricase coupled to monomethoxy polyethylene glycol that is approved in the US for treatment of patients with chronic refractory…
Abstract Number: 1221 • 2019 ACR/ARP Annual Meeting
Impact of Psoriasis Disease Activity and Other Risk Factors on Serum-urate Levels in Patients with Psoriasis and Psoriatic Arthritis – A Post-hoc Analysis of Pooled Data from Three Phase 3-trials with Secukinumab
Mats Dehlin¹, Andreas Fasth ², Maximilian Reinhardt ³ and Lennart Jacobsson ⁴, ¹Dept of Rheumatology and Inflammation Research, Institute of Medicine, Sahlgrenska Academy, University of Gothenburg, Sweden, Gothenburg, Sweden, ²Medical Affairs, Novartis Sverige AB, Kista, Sweden, Stockholm, Sweden, ³Medical Affairs, Novartis Pharma GmbH, Nürnberg, Germany, Nürnberg, Germany, ⁴Dept of Rheumatology and Inflammation Research, Institute of Medicine, Sahlgrenska Academy, University of Gothenburg, Sweden,, Gothenburg, Sweden
Background/Purpose: Increased serum uric acid (sUA), hyperuricemia, has been reported to be associated with psoriasis (1). Increased cell turnover in psoriatic skin lesions has been…
Abstract Number: 1223 • 2019 ACR/ARP Annual Meeting
Enteral Administration of ALLN-346, a Recombinant Urate-degrading Enzyme, Decreases Serum Urate in a Pig Model of Hyperuricemia
Danica Grujic¹, Kateryna Pirzynowska ², Paulina Szczurek ³, Stefan Pierzynowski ², Aditi Desphande ⁴, Olha Drahanchuck ⁵, Nadia Mosiichuk ⁶ and Jarek Wolinski ⁷, ¹Allena Pharmaceuticals, Boston, ²Lund University, Anara AB,/SGPlus, Lund, Sweden, ³National Research Institute of Animal Production, Vitanano Sp. z o.o./PROF,, Balice, Poland, ⁴Allena Pharmaceuticals, Newton, MA, ⁵Polish Academy of Sciences, Vitanano Sp. z o.o./PROF,, Jablonna, Poland, ⁶Lund University, Lund, Sweden, ⁷Polish Academy of Sciences, Vitanano Sp. z o.o./PROF, Jablonna, Poland
Background/Purpose: Uric acid homeostasis is determined as a balance between production, intestinal secretion and renal excretion. Around 2/3 of uric acid is excreted by the…
Abstract Number: 1229 • 2019 ACR/ARP Annual Meeting
AR882, a Potent and Selective Uric Acid Lowering Agent Acting Through Inhibition of Uric Acid Reuptake, Shows Excellent Pharmacokinetics and Pharmacodynamics in a Phase 1 Clinical Trial
zancong shen ¹, Elizabeth Polvent ², Vijay Hingorani ³, Shunqi Yan ⁴, Rongzi Yan ⁴ and Litain Yeh⁴, ¹Arthrosi Therapeutics, San Diego, CA, ²Arthrosi Therapeutics, Laguna Hills, CA, ³Arthrosi Therapeutics, San Diego, ⁴Arthrosi Therapeutics, Laguna Hills
Background/Purpose: AR882 is a potent and selective uric acid transporter 1 (URAT1) inhibitor under development for the treatment of hyperuricemia or gout. A Phase 1…
Abstract Number: 1233 • 2019 ACR/ARP Annual Meeting
Identification and Characterization of a Novel Dysfunction Variant p.I242T in ABCG2 Transporter in a Family with Early-onset Hyperuricamia and Gout
Blanka Stiburkova¹, Yu Toyoda ², Katerina Pavelcova ³, Martin Klein ⁴, Tappei Takada ² and Hiroshi Suzuki ², ¹Institute of Rheumatology; Department of Pediatrics and Adolescent Medicine, First Faculty of Medicine, Charles University and General University Hospital in Prague, Prague, Czech Republic, Prague, Czech Republic, ²Department of Pharmacy, The University of Tokyo Hospital, Tokyo, Japan, Tokyo, Japan, ³Institute of Rheumatology; Department of Rheumatology, First Faculty of Medicine, Charles University, Prague, Czech Republic, Prague, Czech Republic, ⁴Institute of Rheumatology, Department of Rheumatology, 1st Faculty of Medicine, Prague, Czech Republic, Prague, Czech Republic
Background/Purpose: ABCG2 is a high-capacity urate transporter gene. Common dysfunctional variants of ABCG2 that result in decreased urate excretion in humans are major causes of…
Abstract Number: 1234 • 2019 ACR/ARP Annual Meeting
Inconsistency in Uric Acid Reference Ranges Among 20 Top United States Hospitals: What Is “Normal”?
Brittany Frankel¹, Grant Hughes ¹ and Mark Wener ¹, ¹University of Washington, Seattle, WA
Background/Purpose: Elevated serum uric acid (UA) concentration is associated with the urate crystal deposition disorders gout and nephrolithiasis, as well as hypertension, the metabolic syndrome,…
Abstract Number: 2051 • 2019 ACR/ARP Annual Meeting
Factors in Achieving Serum Uric Acid Target and the Occurrence of Gouty Arthritis: A Cross-sectional Study Based on Japanese Health Insurance Claim Data
Ruriko Koto¹, Akihiro Nakajima ¹, Hideki Horiuchi ¹ and Hisashi Yamanaka ², ¹Teijin Pharma Limited, Chiyoda-ku, Tokyo, Japan, ²Sanno Medical Center, Minato-ku, Tokyo, Japan
Background/Purpose: The number of gout attacks can be reduced by achieving and maintaining serum uric acid (sUA) at or below 6.0 mg/dL, a level uniformly…
Abstract Number: 2065 • 2019 ACR/ARP Annual Meeting
Association Between Anemia and Hyperuricemia: Korean National Health and Nutrition Survey 2016-2017
Seulkee Lee¹, Yeonghee Eun ¹, Jiwon Hwang ², Hoon-Suk Cha ¹, Eun-Mi Koh ¹, Jaejoon Lee ¹ and Hyungjin Kim ¹, ¹Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea, ²Samsung Changwon Hospital, Sungkyunkwan University School of Medicine, Changwon, Republic of Korea
Background/Purpose: Hyperuricemia and anemia may be related in terms of sharing comorbidities such as chronic kidney disease (CKD) and cardiovascular disease. However, to our knowledge,…
Abstract Number: 2077 • 2019 ACR/ARP Annual Meeting
Population Impact Attributable to Modifiable Risk Factors for Hyperuricemia and the Fallacy of the Variance Explained
Natalie McCormick ¹, Na Lu ², Sharan Rai ³, Chio Yokose ⁴, Yuqing Zhang ⁴ and Hyon K. Choi⁴, ¹Massachusetts General Hospital and Harvard Medical School, Boston, MA, ²Massachusetts General Hosptial, Boston, MA, ³Department of Nutrition, Harvard T.H. Chan School of Public Health, Boston, MA, ⁴Massachusetts General Hospital, Boston, MA
Background/Purpose: In a seminal BMJ paper (Prior 1986), the Tokelau Island migrant study for gout and hyperuricemia concluded preventive strategies to modify body mass, diet…
Abstract Number: 2837 • 2019 ACR/ARP Annual Meeting
Asymptomatic Monosodium Urate Crystal Deposition Associates with Increased Expression of Pro-Inflammatory Genes
Gabriela Sandoval-Plata¹, Kevin Morgan ², Tamar Guetta-Baranes ², Ana Valdes ³, Michael Doherty ⁴ and Abhishek Abhishek ⁵, ¹Human Genomics and Molecular Genetics, School of Life Sciences, University of Nottingham / Academic Rheumatolog, School of Medicine, University of Nottingham, Nottingham, England, United Kingdom, ²Human Genomics and Molecular Genetics, School of Life Sciences, University of Nottingham, Nottingham, England, United Kingdom, ³Academic Rheumatology, School of Medicine, University of Nottingham / Nottingham NIHR BRC, Nottingham UK, Nottingham, England, United Kingdom, ⁴Academic Rheumatology, Division of Rheumatology,School of Medicine, University of Nottingham, Nottingham, UKArthritis Research UK Pain Centre, Nottingham, UKNational Institute for Health Research, Nottingham Biomedical Research Centre, Nottingham, UK, Nottingham, England, United Kingdom, ⁵Academic Rheumatology, School of Medicine, University of Nottingham,Nottingham,UK National Institute for Health Research, Nottingham Biomedical Research Centre, Nottingham,UK, Nottingham, England, United Kingdom
Background/Purpose: Persistent hyperuricaemia is a prerequisite for gout. However, only 10% of people with hyperuricaemia develop symptomatic gout, whereas 25-35% have asymptomatic monosodium urate (MSU)…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].